|
 |
| home > ebr > spring 2004 > protein antigens for therapeutic and diagnostic antibodies biodevelopment and manufacturing |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| The ability to generate specific antibodies to specific defined antigens is now regarded as one of the cornerstone techniques in biotechnology. From research tools to cancer therapeutics, the legacy of Kohler and Milstein by their development of monoclonal hybridoma antibody technologies has been instrumental in shaping the biopharmaceutical industry (1). The generation and production of customised antibodies is a now a multi-billion dollar market, fuelled by the successful development of a new generation of antibody-based therapies for disease afflictions such as breast cancer (Herceptin®, Genentech), acute myeloid leukaemia (Mylotarg®, Wyeth), rheumatoid arthritis and Crohn's disease (Remicade®, Centocor) |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
